Poster Viewing Sessions
Poster Viewing Sessions are organised on Monday 16, Tuesday 17, Wednesday 18 and Thursday 19 November.
During those sessions, Young investigators will reply live and by chat to questions moderated by the session chairs following the broadcasting of their video recorded poster presentation via the live stream.
Hour Location |
Title | Location |
---|---|---|
15:30 |
Poster Viewing Session I - Basic Studies Hans Lassmann, Prof Dr Hartmut Wekerle |
|
15:30 |
ID 28: Endocannabinoid system modulation in peripheral blood mononuclear cells from dimethyl fumarate-treated multiple sclerosis patients Ms Alicia Sánchez Sanz |
|
15:36 |
ID 36: Anterior optic pathway pathology in CNS demyelinating diseases Dr Marco Pisa |
|
15:42 |
ID 45: Is EBV DNA detectable in CSF in multiple sclerosis? Mr Joonas Lehikoinen |
|
15:48 |
ID 54: Fluoxetine modulates Th17-immune response via 5-HT2B-receptors in multiple sclerosis Dr Mikhail Melnikov |
|
15:54 |
ID 57: Dopamine suppresses Th17-cells function in multiple sclerosis Dr Mikhail Melnikov |
|
16:00 |
ID 62: Effects of different Myelin Oligodendrocyte Glycoprotein dosage on visual function in the Dark Agouti rat model of Experimental Autoimmune Encephalomyelitis Dr Valerio Castoldi |
|
16:06 |
ID 77: A case of autoimmune GFAP astrocytopathy diagnosed after long term diagnosis of CLIPPERS Dr Hexiang Yin |
|
16:12 |
ID 87: Laboratory detection of antibody in IIDDs Dr Li-Jie Zhang |
|
16:18 |
ID 95: Direct conversion of mouse embryonic fibroblasts toward oligodendrocyte precursor cells Dr Maryam Ghasemi |
|
16:30 |
Poster Viewing Session II - Treatment I Prof Dr Jacqueline Palace, Xavier Montalban |
|
16:30 |
ID 5: Inhalation of Dimethyl Fumarate encapsulated-nanoparticles attenuates clinical signs and central nervous system inflammation of Experimental Autoimmune Encephalomyelitis animals’ models Mrs Bárbara Pinto |
|
16:36 |
ID 6: Characteristics of a population-based multiple sclerosis cohort treated with disease-modifying drugs in a universal healthcare setting Dr Huah Shin Ng |
|
16:42 |
ID 9: Delayed and recurrent dimethyl fumarate induced-lymphopenia in patients with Multiple Sclerosis. Dr Serena Borrelli |
|
16:48 |
ID 11: Effects of smoking on lymphocyte subpopulations in patients with MS on dimethyl fumarate Ms Maria-Elizabeth Baeva |
|
16:54 |
ID 14: Characterization of cladribine tablets treated MS patients in Finland Mr Ilkka Rauma |
Hour Location |
Title | Location |
---|---|---|
15:30 |
Poster Viewing Session III - Investigations Ludwig Kappos, Letizia Leocani |
|
15:30 |
ID 8: Structural constraints of functional connectivity drive cognitive impairment in the early stages of multiple sclerosis Dr Ismail Koubiyr |
|
15:36 |
ID 23: MR T2-relaxation time as an indirect measure of brain water accumulation in Neuromyelitis Optica Spectrum Disorders Dr Laura Cacciaguerra |
|
15:42 |
ID 52: Retinal neuro-axonal loss parallels global disability accrual in progressive multiple sclerosis independently from disease activity Dr Simone Guerrieri |
|
15:48 |
ID 56: Serum neurofilaments predict recovery after acute optic neuritis Dr Gloria Dalla Costa |
|
15:54 |
ID 63: Functional and structural visual pathway alterations in experimental autoimmune encephalomyelitis mouse model Dr Silvia Marenna |
|
16:00 |
ID 64: The relationship between cerebellar volume, clinical disability and cognitive changes in MS patients Dr Onural Ozturk |
|
16:06 |
ID 86: The cerebellar peduncle lesion as an age-independent feature of MOG antibody associated disease Dr Yuki Matsumoto |
|
16:12 |
ID 88: SWI enhances vein detection using UPSIO in multiple sclerosis Dr Li-Jie Zhang |
|
16:20 |
Poster Viewing Session IV - Treatment II Patrick Vermersch, Hans-Peter Hartung |
|
16:20 |
ID 16: Propensity-matched comparison of early intensive and escalation treatment strategy in Finnish MS patients Dr Katariina Hänninen |
|
16:26 |
ID 20: Assessing the real-world effectiveness of ocrelizumab in patients with multiple sclerosis – CONFIDENCE one-year interim analysis Dr Julius Eggebrecht |
|
16:32 |
ID 21: Safety and tolerability in patients with multiple sclerosis receiving ocrelizumab in a real-world setting – CONFIDENCE one-year interim analysis Dr Julius Eggebrecht |
|
16:38 |
ID 43: Secondary Autoimmune Diseases following Ocrelizumab Therapy for Multiple Sclerosis Dr Sophie Elands |
|
16:44 |
ID 58: Therapeutic Plasma Exchange Effect on Neuromyelitis Optica Spectrum Disorder Dr Enrique Gomez-Figueroa |
|
17:00 |
ID 71: Rituximab in Multiple Sclerosis: B-lymphocyte population study and its relationship with dosing regimen Dr Inês Cunha |
Hour Location |
Title | Location |
---|---|---|
15:30 |
Poster Viewing Session V - Clinical I Prof Dr Alexey Boyko, Prof Dr Edgardo Cristiano |
|
15:30 |
ID 3: Stable vs. Silent progressive Multiple Sclerosis: A real world retrospective clinical imaging Brazilian study Ms Raquel Custódio Da Silveira |
|
15:36 |
ID 12: Information in Multiple Sclerosis: do people with MS want to know about their disease? Dr Elisa Matias Vieira de Melo |
|
15:42 |
ID 26: Efficacy of high-intensity aerobic exercise on fatigue, walking, and quality of life in people with multiple sclerosis: A randomized controlled trial Dr Martin Langeskov-Christensen |
|
15:48 |
ID 39: Concomitant onset of Multiple Sclerosis and celiac disease: association or new disease entity? Dr Gaia Cola |
|
15:54 |
ID 42: Anti-NMDAR autoimmune encephalitis in Covid-19 pneumonia patient Dr Erasmo Ramos |
|
16:00 |
ID 44: The Concurrence of Multiple Sclerosis and Glioma Dr Sophie Elands |
|
16:10 |
Poster Viewing Session VI - Epidemiology I Oscar Fernández, Per Soelberg Sørensen |
|
16:10 |
ID 2: Smoking and multiple sclerosis risk: A Mendelian randomization study Ms Marijne Vandebergh |
|
16:16 |
ID 4: Demographic poor prognostic factors in Mexican patients with multiple sclerosis Dr Ricardo García-Bermúdez |
|
16:22 |
ID 17: Multiple Sclerosis after Primary Central Nervous System Cancer in Mexican Population Dr Marlene Arbeu-Reyes |
|
16:28 |
ID 25: Functional survey of the pediatric multiple sclerosis microbiome Mr Ali Mirza |
|
16:34 |
ID 29: A systematic review and meta-analysis of the prevalence of multiple sclerosis in patients with uveitis and characterisation of the phenotype of patients with both conditions Dr Thomas Taylor |
|
16:40 |
ID 35: Subclinical anterior optic pathway involvement in early multiple sclerosis and clinically isolated syndromes Dr Marco Pisa |
|
16:46 |
ID 47: Probing gene-environment interactions in the pathogenesis of Multiple Sclerosis using UK Biobank Dr Benjamin Jacobs |
Hour Location |
Title | Location |
---|---|---|
15:30 |
Poster Viewing Session VII - Clinical II Bernard M.J. Uitdehaag, Gilles Edan |
|
15:30 |
ID 50: Identifying distinct cognitive phenotypes in multiple sclerosis Dr Ermelinda De Meo |
|
15:36 |
ID 53: Central and peripheral (CCDP) demyelination in a patient with MOGAD disease(MOG Antibody disease) Mr Konstantinos Melanis |
|
15:42 |
ID 60: Diffuse B giant cell lymphoma associated with fingolimod treatment in Multiple Sclerosis: a case report Dr Adriana Casallas Vanegas |
|
15:48 |
ID 65: A Genome-Wide Association Study highlights a possible involvement of mast cells and neutrophils in disease activity in multiple sclerosis Dr Antonino Giordano |
|
15:54 |
ID 70: Predominant cognitive phenotypes in MS: insights from patient-centered outcomes (PCOs) Dr Jessica Podda |
|
16:00 |
ID 84: Clinical characteristics of patients with late-onset NMOSD in a Japanese cohort Mr Akihiro Nakajima |
|
16:15 |
Poster Viewing Session VIII - Epidemiology II Maria Trojano, Prof Dr Kazuo Fujihara |
|
16:15 |
ID 49: Cardiovascular risk factors affect brain volume in young multiple sclerosis patients Dr Raffaello Bonacchi |
|
16:21 |
ID 59: Multiple Sclerosis-related Optic Neuritis: A retrospective observational study Dr Sofia Bezerra de Oliveira Costa |
|
16:27 |
ID 61: Comorbidity and persistence of disease-modifying therapy use for relapsing remitting multiple sclerosis Dr Natalie Parks |
|
16:33 |
ID 66: Fine particulate matter related to multiple sclerosis relapse in young patients Dr Edouard Januel |
|
16:39 |
ID 69: Is salt consumption an environmental risk factor for multiple sclerosis? Dr Sena Destan Bunul |
|
16:45 |
ID 72: MS risk/protection factors: A Moroccan study Dr Hind Gouiti |